KromaTiD

KromaTiD has established itself as a specialized contract research organization (CRO) and lab focused exclusively on single-cell genomic visualization and analysis. The company's KROMASURE™ Platform utilizes advanced fluorescent hybridization technology to provide orthogonal confirmation for sequencing data, critical for IND submissions and batch release testing in cell and gene therapy development. By offering services from research through GLP/GMP-compliant testing, KromaTiD addresses the growing need for definitive genomic integrity data to ensure therapy safety and efficacy. Its business model is built on providing essential analytical services and platform data to biotech, pharma, and regulatory partners.

KROMASURE™ Platform: A suite of advanced fluorescent in situ hybridization (FISH) and cytogenetic assays for single-cell visualization and analysis of genomic integrity, structural variants, and transgene mapping. It provides orthogonal, high-resolution data to complement next-generation sequencing.

KromaTiD competes with broad-based CROs offering cytogenetic services and with genomics companies advancing long-read sequencing and bioinformatic tools for structural variant detection. Its key differentiation is an exclusive focus on single-cell visualization, providing direct, unambiguous data that sequencing infers indirectly.